The clinical benefit of confirming pathological DAT availability is negligible in patients with a clear metabolic pattern of PD (i.e. hypometabolism in the temporoparietooccipital cortex), MSA (i.e., hypometabolism in the posterior putamen and cerebellum), or PSP (i.e., hypometabolism in the medial and dorsolateral frontal cortex, caudate, and thalamus)5. This evidence concerns the gene SLC6A3 and multiple system atrophy.